ICU Medical stock analysis
ICU Medical (IC7) Stock Price & Analysis
IC7 Stock Chart & Stats
- Day’s Range
- EUR 156.00 - EUR 161.00
- 52-Week Range
- EUR 97.00 - EUR 163.00
- Previous Close
- EUR 160.00
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 4.02B
- Enterprise Value
- EUR 4.94B
- Total Cash (Recent Filing)
- EUR 301.78M
- Total Debt (Recent Filing)
- EUR 1.15B
- Price to Earnings (P/E)
- 74.4
- Beta
- 0.53
- Next Earnings
- Mar 03, 2027 (Est.)
- EPS Estimate
- 1.94
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And Deleveraging
Strong operating and free cash flow gives ICU Medical internal funding capacity for product development, integration and debt reduction. The concurrent decline in leverage improves financial resilience and should support more flexible capital allocation over the next several quarters.
Infusion And Consumables Growth With Margin Expansion
Growth in higher-margin Infusion Systems and recurring Consumables is improving both mix and profitability. This combination can make earnings more durable because pump placements support consumable pull-through while hospital utilization sustains repeat demand.
Product Innovation And Connected-platform Roadmap
A connected infusion platform can deepen ICU Medical's role in hospital workflows and create a broader product ecosystem. Combining software integration with new pump and disposable launches may strengthen customer retention and support recurring demand over time.
Bears Say
Vital Care Contraction And Logistics Disruption
The Vital Care decline shows that integration and distribution changes can disrupt execution and product availability across the portfolio. Continued weakness would dilute the benefit of stronger Infusion Systems performance and pressure consolidated growth and mix.
Regulatory Timing And Remediation Burden
Additional testing can delay product launches, postpone revenue from the development pipeline and extend compliance costs. Ongoing quality-system and EU MDR remediation also consume cash and management attention, limiting near-term operating leverage.
Modest Earnings Power And Uneven Revenue Trend
Despite recovering margins, net profitability remains modest relative to ICU Medical's revenue scale, while recent revenue performance has been uneven. This leaves less earnings cushion if demand or product mix weakens and makes sustained margin execution important.
IC7 FAQ
What was ICU Medical’s price range in the past 12 months?
What is ICU Medical’s market cap?
When is ICU Medical’s upcoming earnings report date?
How were ICU Medical’s earnings last quarter?
Is ICU Medical overvalued?
Does ICU Medical pay dividends?
What is ICU Medical’s EPS estimate?
How many shares outstanding does ICU Medical have?
What happened to ICU Medical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ICU Medical?
What is the TipRanks Smart Score and how is it calculated?
ICU Medical Stock Smart Score
Company Description
ICU Medical
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Vivek Jain
- Employees
- 13,000
- Website
- www.icumed.com
- Address
- 951 Calle Amanecer, San Clemente, CA, 92673, US
ICU Medical (IC7) Earnings & Revenues
IC7 Company Deck
IC7 Earnings Call
Earnings Call SentimentPositive
The call was broadly positive. The company reported solid revenue, EBITDA, EPS and free cash flow performance; record results in Infusion Systems and Consumables; improving gross margins; lower integration spending; debt reduction; and guidance toward the high end of its ranges. These strengths outweighed the stated challenges, including Vital Care's decline, logistics disruptions, tariff and FX pressures, ongoing remediation spending and approval timing for certain products.
View all DE:IC7 earnings summariesIC7 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 1 | 5 |
| Technical Analysis | 4 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |
